Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2020 Net Sales

Author's Avatar
Jan 13, 2021
Article's Main Image

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2020.